IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ning Hu et al.

Title: METHOD OF DRUG LOADING IN LIPOSOMES BY GRADIENT

Docket No.: 1992.007US1
Filed: November 26, 2003
Examiner: Unknown

Serial No.: 10/723,431
Due Date: N/A
Group Art Unit: 1615

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

X A return postcard.
X A Communication Concerning Related Applications (1 pg.).
X An Information Disclosure Statement (2 pgs.), Form 1449 (4 pgs.), and copies of 41 cited documents.
X Copy of International Search Report from Corresponding Foreign Application No. PCT/US 03/37964 (11 pgs.).

Please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
Customer Number 21186

By: _____
Atty: Gary J. Speier
Reg. No. 45,458

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 9 day of February, 2005.

Name _____ Signature _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Ning Hu et al.	Examiner: Unknown
Serial No.:	10/723,431	Group Art Unit: 1615
Filed:	November 26, 2003	Docket: 1992.007US1
Title:	METHOD OF DRUG LOADING IN LIPOSOMES BY GRADIENT	

COMMUNICATION CONCERNING RELATED APPLICATIONS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Applicants would like to bring to the Examiner's attention the following related applications in the above-identified patent application:

Serial/Patent No.	Filing Date	Attorney Docket	Title
10/723,423	November 26, 2003	1992.005US1	LIPOSOMAL FORMULATIONS

Respectfully submitted,

NING HU ET AL.

By Applicants' Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 359-3261

Date 2/7/05 By _____
Gary J. Speier
Reg. No. 45,458

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 9 day of February, 2005.

Name _____ Signature _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Ning Hu et al.	Examiner:	Unknown
Serial No.:	10/723,431	Group Art Unit:	1615
Filed:	November 26, 2003	Docket:	1992.007US1
Title:	METHOD OF DRUG LOADING IN LIPOSOMES BY GRADIENT		

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Respectfully submitted,
NING HU ET AL.

By their Representatives,
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 359-3261

Date 2/7/05 By _____
Gary J. Speier
Reg. No. 45,458

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 9 day of February, 2005.

Name _____ Signature _____

PTO/SB/08A(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/723,431
Filing Date	November 26, 2003
First Named Inventor	Hu, Ning
Group Art Unit	1615
Examiner Name	Unknown

Sheet 1 of 4

Attorney Docket No: 1992.007US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-3,993,754	11/23/1976	Rahman, Yueh-Erh , et al.	10/09/1974
	US-4,145,410	03/20/1979	Sears, Barry D.	06/17/1997
	US-4,224,179	09/23/1980	Schneider, Michel	09/23/1980
	US-4,235,871	11/25/1980	Papahadjopoulos, Demetrios P., et al.	02/24/1978
	US-4,522,803	06/11/1985	Lenk, Robert P., et al.	03/24/1983
	US-4,588,578	05/13/1986	Fountain, Michael W., et al.	08/08/1983
	US-4,753,788	06/28/1988	Gamble, Ronald C.	01/31/1985
	US-4,885,172	12/05/1989	Bally, M. B., et al.	12/15/1986
	US-4,938,949	07/03/1990	Borch, Richard F., et al.	09/12/1988
	US-4,946,683	08/07/1990	Forssen, Eric A.	08/04/1989
	US-5,077,056	12/31/1991	Bally, M. B., et al.	12/12/1988
	US-5,316,771	05/31/1994	Barenholz, Yechezkel , et al.	12/18/1992
	US-5,380,531	01/10/1995	Chakrabarti, Ajoy , et al.	06/02/1992
	US-5,616,341	04/01/1997	Mayer, L. D., et al.	08/26/1993
	US-5,795,589	08/18/1998	Mayer, Lawrence D., et al.	02/05/1997
	US-5,814,335	09/29/1998	Webb, Murray S., et al.	09/17/1997
	US-6,083,530	07/04/2000	Mayer, Lawrence D., et al.	05/26/1998

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T[2]
	EP-0290296A2	11/09/1988	Bally, M. B., et al.	
	EP-0546951A1	06/16/1993	Ostro, Marc J.	
	EP-0719546A1	07/03/1996	Bally, Marcel B., et al.	
	WO-0105372A2	01/25/2001	Abra, R. M., et al.	
	WO-03041682A3	05/22/2003	Webb, Murray , et al.	
	WO-8601102A1	02/27/1986	Bally, Marcel B., et al.	
	WO-8700238	01/15/1987	Rudham, Robert C., et al.	
	WO-9202244A1	02/20/1992	Chakrabarti, A. , et al.	
	WO-9913816A2	03/25/1999	Moynihan, Karen L., et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		"International Search Report, for Application No. PCT/US 03/37964, date mailed July 5, 2004", 11 Pages	
		ADLAKHA-HUTCHEON, G. , et al., "Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity", Nature Biotechnology, 17(8), (August 1999),775-779	

EXAMINER **DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

PTO/SB/08A(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/723,431
Filing Date	November 26, 2003
First Named Inventor	Hu, Ning
Group Art Unit	1615
Examiner Name	Unknown

Sheet 2 of 4

Attorney Docket No: 1992.007US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		BANDAK, S. , et al., "Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models", Anticancer Drugs, 10, (November 10, 1999),911-920	
		BANGHAM, A D., "Diffusion of univalent ions across the lamellae of swollen phospholipids", Journal of Molecular Biology, 13(1), (August 1965),238-52	
		COLBERN, C. T., et al., "Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model", Journal of Inorganic Biochemistry, 77(1-2), (October 1999),117-120	
		CRAMER, J. A., "NMR Studies of pH-Induced Transport of Carboxylic Acids Across Phospholipid Vesicle Membranes", Biochemical and Biophysical Research Communications, 75(2), (1977),295-301	
		DEAMER, DAVID W., et al., "Liposome Preparation: Methods and Mechanisms", Chapter 1 - In: Liposomes by Marc Ostro, New York : M. Dekker,(1983),27-51	
		DEAMER, D W., et al., "The response of fluorescent amines to pH gradients across liposome membranes", Biochimica et Biophysica Acta, 274(2), (August 9, 1972),323-35	
		DEMARIO, M. D., et al., "A Phase I Study of Liposome-Formulated Cisplatin (SPI-77 R) Given Every 3 Weeks in Patients With Advanced Cancer", Proceedings of ASCO, Vol. 17, http://www.asco.org/ac/1,1003,_12-002643-00_18-0031-00_19-006314,00.asp,(1998),Abstract 883	
		FORSSEN, E A., "Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes", Cancer Research, 43(2), (February 1983),546-50	
		GABIZON, A , "Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers", Cancer Research, 43(10), (October 1983),4730-5	
		GABIZON, A , "Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice", Cancer Research, 42(11), (November 1982),4734-9	
		GANAPATHI, R , "Effect of cholesterol content of liposomes on the encapsulation, efflux and toxicity of adriamycin", Biochem Pharmacol., 33(4), (February 15, 1984),698-700	
		HARRINGTON, K. J., et al., "Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer", Annals of Oncology, 12(4), (April 2001),493-496	
		HERMAN, E H., et al., "Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation", Cancer Research, 43(11), (November 1983),5427-32	

EXAMINER **DATE CONSIDERED**

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

PTO/SB/08A(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/723,431
Filing Date	November 26, 2003
First Named Inventor	Hu, Ning
Group Art Unit	1615
Examiner Name	Unknown

Sheet 3 of 4

Attorney Docket No: 1992.007US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
		HONG, R L., et al., "Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice is surface coating with polyethylene glycol beneficial?", Clinical Cancer Research, 5(11), (November 1999),3645-3652	
		LIM, H. J., et al., "Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone", The Journal of Pharmacology and Experimental Therapeutics, 281(1), (April 1997),566-573	
		LOPEZ-BERESTEIN, G , et al., "Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study", The Journal of Infectious Diseases, 151(4), (April 1985),704-10	
		MEERUM TERWOGT, J. M., et al., "Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin", Cancer Chemotherapy and Pharmacology, 49(3), (March 2002),201-210	
		MINOW, ROBERT A., "Adriamycin (NSC-123127) Cardiomyopathy - An Overview with Determination of Risk Factors", Cancer Chemother Reports, Part 3, 6(2), (October 1975),195-201	
		NEWMAN, M. S., et al., "Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice", Cancer Chemotherapy and Pharmacology, 43(1), Erratum in Cancer Chemotherapy and Pharmacology, 43(6), 524 (attached to downloaded document),(1999),1-7	
		OLSON, F , "Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes", European Journal of Cancer & Clinical Oncology, 18(2), (February 1982),167-76	
		PAPAHADJOPOULOS, D , "Phospholipid model membranes. I. Structural characteristics of hydrated liquid crystals", Biochimica et Biophysica Acta, 135(4), (September 9, 1967),624-638	
		RAHMAN, A , "Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration", Cancer Research, 42(5), (May 1982),1817-25	
		RAHMAN, A , "Liposomal protection of adriamycin-induced cardiotoxicity in mice", Cancer Research, 40(5), (May 1980),1532-7	
		RAHMAN, A , "Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes", Cancer Research, 45(2), (February 1985),796-803	
		RICHARDSON, V , "Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients", British Journal of Cancer, 40(1), (July 1979),35-43	
		ROSA, P , "Absorption and tissue distribution of doxorubicin entrapped in liposomes following intravenous or intraperitoneal administration", Pharmacology, 26(4), (1983),221-9	

EXAMINER **DATE CONSIDERED**

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional) [2] Applicant is to place a check mark here if English language Translation is attached

PTO/SB/08A(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*	*Complete if Known*	
	Application Number	10/723,431
	Filing Date	November 26, 2003
	First Named Inventor	Hu, Ning
	Group Art Unit	1615
	Examiner Name	Unknown
Sheet 4 of 4	Attorney Docket No: 1992.007US1	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	**Cite No [1]**	**Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.**	**T[2]**
		ROSA, P. , et al., "Liposomes containg Doxorubicin - an example of drug targeting", In: Transport in biomembranes : model systems and reconstitution edited by Rezo Antolini, New York : Raven Press,(1982),243-256	
		RYMAN, BRENDA E., et al., "Liposomes: Further Considerations of their possible role as carriers of therapeutic agents", In: Targeting of drugs edited by Gregory Gregoriadis, New York : Plenum Press,(1982),235-248	
		SZOKA, F. , "Comparative properties and methods of preparation of lipid vesicles (liposomes).", Annual Review of Biophysics and Bioengineering, 9, (1980),467-508	
		VEAL, G. J., et al., "A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin", British Journal of Cancer, 84(8), (April 2001),1029-1035	
		WORKING, P. K., et al., "Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys", Toxicological Sciences, 46(1), (November 1998),155-165	

EXAMINER **DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached